Inovio Pharmaceuticals Inc. (INO) News
Filter INO News Items
INO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INO News Highlights
- INO's 30 day story count now stands at 8.
- Over the past 26 days, the trend for INO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about INO are AMC, ALKS and BEAT.
Latest INO News From Around the Web
Below are the latest news stories about Inovio Pharmaceuticals Inc that investors may wish to consider to help them evaluate INO as an investment opportunity.
Thinking About Buying Stock In AMC Entertainment, Romeo Power Or Inovio Pharmaceuticals?Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for AMC Entertainment Holdings Inc (NYSE: AMC ), Romeo Power Inc (NYSE: RMO ) and Inovio Pharmaceuticals Inc (NASDAQ: INO ): The latest price target for AMC was by Wedbush on Nov. 4. The analyst firm set a price target … Full story available on Benzinga.com |
Shareholders in Inovio Pharmaceuticals (NASDAQ:INO) have lost 78%, as stock drops 12% this past weekAs every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept... |
Alkermes (ALKS) Q4 Earnings and Revenues Beat EstimatesAlkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. |
Molina Healthcare (MOH) Q4 Earnings Beat on Higher PremiumsMolina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results. |
Humana (HUM) Q4 Earnings Beat Estimates on Membership GrowthHumana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities. |
Could Inovio Pharmaceuticals Become the Next Moderna?When it comes to biotechs, Moderna (NASDAQ: MRNA) is the standard to beat. On the surface, Inovio is very much in the same position that Moderna was before the pandemic. With a market cap close to $900 million, it doesn't have any recurring revenue or any medicines that are approved for sale, and its coronavirus vaccine program is what originally put it in the limelight in 2020. |
2 Stocks to Avoid Like the Plague in 2022The stock market hasn't been in the best shape this year. Growth stocks have been hit particularly hard due to valuation concerns and impending interest rate hikes in the U.S. All these issues are merely temporary, though, and it'd be best for investors to look past them and hold on to shares of great companies. Let's consider two such stocks: Inovio Pharmaceuticals (NASDAQ: INO) and Cronos Group (NASDAQ: CRON). |
Here's Why Inovio (INO) Looks Ripe for Bottom FishingInovio (INO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |